[1] Roche B, Samuel D. Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients. Clin Liver Dis, 2013, 17: 451-473.
[2] 张翠芳, 罗鹏程, 吴勇波, 等. 拉米夫定抗病毒治疗对TACE治疗原发性肝癌疗效的影响. 实用肝脏病杂志, 2013, 16: 554-555.
[3] 文正燕, 孙传俊. 抗病毒治疗对失代偿肝硬化患者生存时间及肝癌发生的影响. 中国实用医药, 2013, 28: 63-64.
[4] Ji F, Zhang S, Deng H, et al. Efficacy of interferon-based antiviral therapy on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: Further evidence in decompensation cirrhosis. J Hepatol, 2013, 58: 1262-1264.
[5] Srivastava M, Rungta S, Dixit VK, et al. Predictors of survival in hepatitis B virus related decompensated cirrhosis on tenofovir therapy: an Indian perspective. Antiviral Res, 2013, 100: 300-305.
[6] 苗雅娇, 赵守松. 40例慢性乙型肝炎轻度患者肝组织病理学变化研究. 实用肝脏病杂志, 2012, 15: 7-9.
[7] Jonas MM, Block JM, Haber BA, et al. Treatment of children with chronic hepatitis B virus infection in the United States: patient selection and therapeutic options. HepatolInt, 2010, 52: 2192-2205.
[8] 张雪华, 李仲平. 核苷和核苷酸类药物治疗乙型肝炎肝硬化失代偿期患者的临床效果. 临床肝胆病杂志, 2015, 31: 365-369. |
